Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in oral drug delivery platforms, announced its attendance at the BIO International Convention from June 22-25 in San Diego, CA. The company’s participation comes as part of a broader business development (BD) program that has generated record-high levels of interest in its proprietary DehydraTECH platform.
According to a press release, Lexaria’s attendance at last year’s 2025 BIO convention served as a catalyst for its greatly expanded BD program, which is now starting to deliver positive results. The company intends to build upon this momentum at this year’s conference.
“We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference,” said Richard Christopher, CEO of Lexaria Bioscience. “New business relationships require intense energy and scientific evaluation from both prospective partners to discover the best fit possible. We are working tirelessly in this regard with the intent of generating positive developments that we can publicly discuss.”
The BIO International Convention is the largest event of its kind, with over 20,000 attendees expected from the global pharmaceutical and biotechnology industries, as well as investors and finance professionals. The conference focuses on intra-industry collaborations, with over 66,000 partnering meetings taking place at the 2025 event. Lexaria has already begun reserving meetings and will be fully booked given strong industry interest in its DehydraTECH drug delivery platform.
BIO is only the latest example of a multi-faceted BD program that Lexaria quietly launched to inform prospective business partners of the benefits available through DehydraTECH. Although confidential information cannot be publicly disclosed, Lexaria’s BD program has already generated a number of collaborative and potential business partnering discussions with a wide range of companies, from innovative smaller biotech developers to well-known global pharmaceutical giants.
While Lexaria’s BD program has developed several ongoing discussions, it continues to develop additional early-stage leads. The company intends to thoroughly evaluate each potential relationship, large and small, and ultimately only pursue those that are in the best interests of its shareholders. Additional information will be made available when appropriate.
DehydraTECH is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way drugs enter the bloodstream through oral delivery. The technology has repeatedly demonstrated the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood-brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, visit www.lexariabioscience.com.
The implications of Lexaria’s expanding business development efforts are significant for the pharmaceutical industry. If the DehydraTECH platform proves successful in partnering with major drug companies, it could lead to improved oral delivery of a wide range of therapeutics, potentially enhancing patient compliance and treatment outcomes. For Lexaria’s shareholders, successful collaborations could translate into licensing revenues and increased valuation. The company’s focused BD program, as evidenced by its attendance at BIO, signals a strategic push to commercialize its technology, which could reshape oral drug delivery standards.
